Skip To Main Content
Jonathan D. Alpern on Muck Rack

Jonathan D. Alpern

As seen in: Postgraduate Medical Journal, JAMA (The Journal of the American Medical Association), JAMA: Journal of the American Medical Association, The Boston Globe, The New England Journal of Medicine, STAT, Annals of Internal Medicine, Infectious Diseases News, Journal of the American Pharmacists Association
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Jonathan D.

Contact Jonathan D., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

90-day fills for chronic hepatitis B treatments increased patient adherence

|
By Caitlyn Stulpin Verified, Carol L. DiBerardino Verified, Jonathan D. Alpern
| Infectious Diseases News Verified
Source/Disclosures Disclosures: The authors report no relevant financial disclosures. Source/Disclosures Disclosures: The authors report no relevant financial disclosures. We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Key takeaways: Overall, rates of adherence to entecavir and tenofovir disoproxil fumarate were high among commercially insured adults in the U.S. (83% and 81%, respectively).
Open in Who Shared Issue with article?

Trends in Pricing and Out-of-Pocket Spending on Entecavir Among Commercially Insured Patients, 2014-2018

|
By Jonathan D. Alpern, St Paul, Antonio Ciaccia, Ben Link
| JAMA (The Journal of the American Medical Association) Verified
Research Letter Infectious Diseases January 21, 2022 JAMA Netw Open. 2022;5(1):e2144521. doi:10.1001/jamanetworkopen.2021.44521 Introduction Chronic hepatitis B (CHB) causes significant liver-related morbidity and mortality. Treatment of CHB is cost-effective in the US; however, high out-of-pocket spending on first-line therapy may be a treatment barrier.
Open in Who Shared Issue with article?

Characteristics and Price Increases Among Sole-Source, Off-Patent Drugs in the United States, 2008 to 2018

|
By Jonathan D. Alpern, of Minnesota
| JAMA (The Journal of the American Medical Association) Verified
Key Points español 中文 (chinese) Question Are large price increases common among sole-source, off-patent, off-exclusivity drugs, and what drug attributes are associated with large price increases? Findings In this cross-sectional study of 300 drug products, substantial price increases were common.
Open in Who Shared Issue with article?
See all 10 licensed articles (12 Total)